Increasing Access to Breast Cancer Screening Among Immigrants

Cancer Screening Clinical Trial

Official title:

A Randomized Trial to Increase Access to Breast Cancer Screening by Invitation Language Among Immigrants in Norway

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04672265
• Other study ID #: 19/218
• Secondary ID: 213396
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 15, 2021
• Est. completion date: December 31, 2030

Study information

• Verified date: April 2024
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators aim to test whether inviting immigrants to breast cancer screening with a letter in their mother tongue in addition to the standard letter in Norwegian changes screening uptake in these immigrant groups, compared with a comparable group who receive the invitation in Norwegian only,

Description:

Women in selected immigrant groups according to birth country will be invited to screening and randomized in a 1:1 ratio to receive the screening invitation and information material 1) in the major official native language in the country the invitee is born in addition to Norwegian (intervention group), or 2) only Norwegian (control). The 13 selected countries of origin are Poland, the Philippines, Pakistan, Somalia and Arabic speaking countries (Iraq, Syria, Morocco, Lebanon, Algeria, Egypt, Palestine, Sudan and Tunisia). The five intervention languages will thus be Polish, English, Urdu, Somali and Arabic.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 11355
• Est. completion date: December 31, 2030
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 48 Years to 73 Years

Eligibility

Inclusion Criteria:

• Invited to screening program during the study recruitment period (January 2021-June 2022)

• The registered country of birth of the invitee is one of the following; Poland, Pakistan, Philippines, Somalia, Iraq, Syria, Morocco, Lebanon, Algeria, Egypt, Palestine, Sudan and Tunisia

Exclusion Criteria:

• Not reached with the screening invitation letter because of wrong address or similar

Related Conditions & MeSH terms

• Breast Neoplasms
• Cancer Screening

Intervention

Other:
• Mother tongue and Norwegian
The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.

Locations

Country	Name	City	State
Norway	Oslo University Hospital, Cancer Registry	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Screening attendance	Attendance in breast cancer screening programme (yes/no)	0-6 months after sent screening invitation letter